Characteristics of the 22 patients with CHF
| . | No. (%) or median (range) . |
|---|---|
| Age, y (range) | 70 (49-83) |
| Male/female | 12/10 |
| Diagnosis | |
| CML | 11 (50) |
| CML AP | 4 (18) |
| MPD | 4 (18) |
| CML BP | 2 (9) |
| ALL | 1 (5) |
| Medical history | |
| Hypertension | 10 |
| CAD | 8 (36) |
| CHF | 6 (27) |
| DM | 6 (27) |
| Arrythmia | 3 (14) |
| Cardiomyopathy | 1 (5) |
| Prior IFN-α | 12 (55) |
| Prior anthracyclin | 3 (13) |
| Decreased LVEF | 9 (41) |
| Dose at the time of CHF | |
| 300 mg | 1 (5) |
| 400 mg | 8 (36) |
| 600 mg | 8 (36) |
| 800 mg | 5 (23) |
| Albumin, g/L | 33 (17-49) |
| . | No. (%) or median (range) . |
|---|---|
| Age, y (range) | 70 (49-83) |
| Male/female | 12/10 |
| Diagnosis | |
| CML | 11 (50) |
| CML AP | 4 (18) |
| MPD | 4 (18) |
| CML BP | 2 (9) |
| ALL | 1 (5) |
| Medical history | |
| Hypertension | 10 |
| CAD | 8 (36) |
| CHF | 6 (27) |
| DM | 6 (27) |
| Arrythmia | 3 (14) |
| Cardiomyopathy | 1 (5) |
| Prior IFN-α | 12 (55) |
| Prior anthracyclin | 3 (13) |
| Decreased LVEF | 9 (41) |
| Dose at the time of CHF | |
| 300 mg | 1 (5) |
| 400 mg | 8 (36) |
| 600 mg | 8 (36) |
| 800 mg | 5 (23) |
| Albumin, g/L | 33 (17-49) |
CML AP indicates CML–accelerated phase; CML BP, CML–blastic phase; MPD, myeloproliferative disorders; and CAD, coronary artery disease.